Merck Advances European Regulatory Approval For Keytruda Combination In Bladder Cancer
Key takeaways
- Merck’s Keytruda plus Padcev combo is poised for EU approval, broadening treatment options for bladder‑cancer patients and boosting Merck’s oncology portfolio.
- 47% reduction in event‑free survival events
- 35% reduction in death risk
- 55.8% pathologic complete response rate
What happened
Merck & Co., Inc. (MRK) received a favorable recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use for its Keytruda (pembrolizumab) plus Padcev (enfortumab vedotin) combination as a perioperative treatment for adults with resectable muscle‑invasive bladder cancer.
Why it matters
The recommendation signals that the European Commission may grant marketing authorization for the regimen in the EU, Iceland, Liechtenstein, and Norway by Q4 2026, expanding access to a highly effective therapy that has already cleared the U.S. FDA and the EU for cisplatin‑ineligible patients.
Short-term and longer-term
Short-term. Merck shares dipped 0.66% to $146.18 after the news.
Longer-term. The approval would solidify Merck’s leadership in bladder‑cancer immunotherapy, potentially driving long‑term revenue growth.